Search clinical trials for: cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%

Total 109 results

Allergan

Completed

Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye

Dry Eye Syndromes

United States
Taejoon Pharmaceutical Co., Ltd.

Completed

Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Dry Eye Disease Patients

Dry Eye | Dry Eye Syndromes

Korea, Republic of
Baylor College of Medicine
Allergan

Terminated

The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface (CsA)

Dry Eye

United States
SCAI Therapeutics

Completed

Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis

Dry Eye Syndromes

Korea, Republic of
Boston Sight

Withdrawn

Novel Use of Restasis and PROSE Devices

Ocular Surface Disease

United States
Allergan

Completed

Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%

Dry Eye Disease

United States
Aurinia Pharmaceuticals Inc.

Completed

Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease

Dry Eye

United States
Allergan

Completed

Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis® (EMPOWER)

Dry Eye Syndromes

United States
Mahidol University

Completed

Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye

Stevens-Johnson Syndrome

Thailand
Allergan

Completed

Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium

Pterygium

Singapore, United States, Australia
Allergan

Completed

Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease

Keratoconjunctivitis Sicca

United States
Allergan

Completed

Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients

Dry Eye Syndromes

United States
University of Alabama at Birmingham

Completed

Efficacy of Cyclosporine Ophthalmic Emulsion in the Treatment of Dry Eye Syndrome in Contact Lens Wearers

Contact Lens Wearers With Dry Eye Syndrome

United States
M.D. Anderson Cancer Center
Allergan

Withdrawn

Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel

Epiphora
Allergan

Completed

Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Campus Bio-Medico University

Completed

Cyclosporine 0.1% Eye Drops as Prophylactic Treatment In Cataract Surgery (CSA2020)

Ocular Inflammation | Ocular Surface Disease

Italy
Julian M. Mackay-Wiggan
Allergan

Completed

Restasis for Treatment of Brittle Nails

Brittle Nails

United States
Skye Bioscience, Inc.

Completed

Phase 2, Placebo-Controlled, Study Assessing the Safety and Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Patients With Elevated Eye Pressure

Primary Open Angle Glaucoma | Ocular Hypertension

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease | Myelodysplastic/Myeloproliferative Neoplasms

United States
University of Waterloo
Sun Pharmaceutical Industries Limited

Recruiting

Improving Drop Instillation Comfort of a Cyclosporine A Solution

Dry Eye Disease

Canada
Bausch & Lomb Incorporated
Synteract, Inc.

Completed

Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)

Keratoconjunctivitis Sicca

United States
Johns Hopkins University

Completed

Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis

Atopic Keratoconjunctivitis

United States
Boston Sight
Allergan

Completed

Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% on Application of PROSE Devices for Management of Patients With Ocular Surface Disease

Ocular Surface Disease

United States
Center for Ophthalmic and Vision Research, LLC
Sun Pharmaceutical Industries Limited

Completed

CEQUA for Sjogren's Syndrome Dry Eye

Dry Eye | Dry Eye Syndromes | Sjogren's Syndrome

United States
Allergan

Completed

Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome

Arthritis, Rheumatoid | Lupus Erythematosus, Systemic | Scleroderma, Systemic | Keratoconjunctivitis Sicca | Sjogren's Syndrome

United States
Taejoon Pharmaceutical Co., Ltd.

Recruiting

Evaluating the Efficacy and Safety of TJO-087 in Moderate to Severe Dry Eye Disease Patients

Dry Eye Syndrome

Korea, Republic of
Chengdu University of Traditional Chinese Medicine

Completed

AST Combined With 0.05% Cyclosporin Eye Drop Improve Corneal Nerve Density in Patients With SS Dry Eye (AST/SS)

Dry Eye | Sjogren's Syndrome | Ocular Surface Disease

China
Sun Pharmaceutical Industries Limited

Completed

Effect of Cequa™ in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Hospital Universitario Dr. Jose E. Gonzalez

Recruiting

Evaluation of Safety & Efficacy for the Prevention of Ocular GVHD With Ophthalmic Tacrolimus vs Cyclosporine in Allo-HSCT

Ocular Graft-versus-host Disease

Mexico
Allergan

Completed

Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy (IMPACT)

Dry Eye Syndromes

United States
Meir Medical Center

Unknown

Corneal Tear Film Imaging of the Cornea Before and After Restasis Therapy

Dry Eye Syndrome | Tear Film Insufficiency
Chulalongkorn University
Allergan

Unknown

Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes

Dry Eye

Thailand
Surface Pharmaceuticals, Inc.

Completed

A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Allergan

Completed

Study of Cyclosporine in Post-LASIK Patients

Laser In Situ Keratomileusis

United States
Mahidol University

Completed

Efficacy of 0.05 % Cyclosporine Ophthalmic Emulsion Compare With Tear in Meibomian Gland Dysfunction

Meibomian Gland Dysfunction

Thailand
Allergan

Terminated

Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease

Dry Eye Syndromes

United States
Semmelweis University

Unknown

Autoimmunity in Retinitis Pigmentosa

Retinitis Pigmentosa

Hungary
University of North Carolina, Chapel Hill
Allergan

Completed

Topical Cyclosporine Suspension for the Treatment of Brittle Nails

Brittle Nail Syndrome

United States
Novaliq GmbH

Not yet recruiting

A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine

Dry Eye Disease
Hanlim Pharm. Co., Ltd.

Completed

Study of Tisporin Eye Drops Group and Restasis Eye Drops Group After Treatment, Each Treatment Group Comparisons for Evaluation of Efficacy and Safety in Moderate to Severe Dry Eye Disease (HL_TSPR_302)

Dry Eye Syndromes

Korea, Republic of
Farwaniya Hospital

Recruiting

Clinical Outcomes of Cyclosporine Eye Drops in Management of Herpetic Keratitis

Outcomes of Cyclosporine Eye Drops in Herpetic Keratitis

Kuwait
Hanlim Pharm. Co., Ltd.

Completed

Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group (Cyclosporine)

Dry Eye Syndromes

Korea, Republic of
Novartis

Terminated

Safety and Efficacy of Converting Maintenance Kidney and Liver Transplant Recipients With Abnormal Glucose Metabolism From Tacrolimus to Cyclosporine Micro-emulsion

Tacrolimus-associated Abnormal Glucose Metabolism in Kidney and Liver Transplant Recipients
Toyos Clinic
Sun Pharmaceutical Industries Limited

Recruiting

Clinical Efficacy of Two Topical Dry Eye Drops for Central Corneal Stain Clearing Over 90 Days

Dry Eye

United States
ISDIN

Completed

Efficacy and Tolerability Study of Topical Ciclosporin in a Psoriasis Plaque Test

Psoriasis

Germany
Massachusetts Eye and Ear Infirmary

Terminated

The Prophylactic Use of Topical Cyclosporine A 0.05% to Prevent Graft Versus Host Disease Related Dry Eye

Dry Eye

United States
Taejoon Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety Study of TJCS for Treatment of Moderate to Severe Dry Eye Syndromes

Dry Eye Syndromes

Korea, Republic of
Singapore Eye Research Institute

Unknown

Ikervis for DED Due to GVHD Post Allo-HSCT (Ikervis)

Leukemia (Both ALL and AML) | MDS-EB-1

Singapore
Peking University Third Hospital

Recruiting

The Effect of 0.05% CsA Eye Drops on Post-refractive Surgery Dry Eye

Dry Eye

China
Boehringer Ingelheim

Completed

To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL

Lymphoma, Large B-Cell, Diffuse

Spain, Italy, Belgium

3

Subscribe